Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD
Study sponsor: Tarsus Pharmaceuticals, Inc. · TARS
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-05-18Actual
Enrollment · participants39Actual
Source updated2025-10-01Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.